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Abstract
Background
Melioidosis is an increasingly recognised cause of sepsis and death across South East
Asia and Northern Australia, caused by the bacterium Burkholderia pseudomallei. Risk fac-
tors include diabetes, alcoholism and renal disease, and a vaccine targeting at-risk popula-
tions is urgently required. A better understanding of the protective immune response in
naturally infected patients is essential for vaccine design.
Methods
We conducted a longitudinal clinical and immunological study of 200 patients with melioido-
sis on admission, 12 weeks (n = 113) and 52 weeks (n = 65) later. Responses to whole killed
B. pseudomallei were measured in peripheral blood mononuclear cells (PBMC) by inter-
feron-gamma (IFN-γ) ELIspot assay and flow cytometry and compared to those of control
subjects in the region with diabetes (n = 45) and without diabetes (n = 43).
Results
We demonstrated strong CD4+ and CD8+ responses to B. pseudomallei during acute dis-
ease, 12 weeks and 52 weeks later. 28-day mortality was 26% for melioidosis patients, and
B. pseudomallei-specific cellular responses in fatal cases (mean 98 IFN-γ cells per million
PBMC) were significantly lower than those in the survivors (mean 142 IFN-γ cells per million
PBMC) in a multivariable logistic regression model (P = 0.01). A J-shaped curve association
between circulating neutrophil count and mortality was seen with an optimal count of 4000
to 8000 neutrophils/μl.
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Melioidosis patients with known diabetes had poor diabetic control (median glycated
haemoglobin HbA1c 10.2%, interquartile range 9.2–13.1) and showed a stunted B. pseudo-
mallei-specific cellular response during acute illness compared to those without diabetes.
Conclusions
The results demonstrate the role of both CD4+ and CD8+ T-cells in protection against
melioidosis, and an interaction between diabetes and cellular responses. This supports
development of vaccine strategies that induce strong T-cell responses for the control of
intracellular pathogens such as B. pseudomallei.
Author Summary
Melioidosis is a key cause of death in South East Asia and Northern Australia. It is caused
by the soil-dwelling bacteria Burkholderia pseudomallei, and presents as a range of clinical
illnesses including pneumonia and bloodstream infections. About two-thirds of patients
with melioidosis in Thailand have diabetes, but the immune responses associated with
death and diabetes are unknown. This study examined the relationship between immune
responses to the bacteria and death by studying the bacteria-specific lymphocyte responses
in 200 patients admitted to hospital with acute melioidosis and following the patients for
up to one year where possible. 26% of patients died within 28 days despite receiving antibi-
otics and supportive care. We showed people with melioidosis make bacteria-specific lym-
phocyte responses, with lower levels seen in fatal cases compared to survivors. People with
diabetes make lower responses than people without diabetes, and higher levels of circulat-
ing neutrophils on admission to hospital were associated with lower lymphocyte responses
both during illness and three months later in survivors. This highlighting of lymphocyte
responses to melioidosis is important for the design of vaccines to target at risk groups.
Introduction
Melioidosis is a severe and often fatal disease common in Southeast Asia and Northern Austra-
lia, caused by the soil-dwelling bacterium Burkholderia pseudomallei. The main routes of infec-
tion are skin inoculation, inhalation, and ingestion of the organism from the environment [1].
The known risk factors are diabetes, alcoholism, renal disease and increasing age, with HIV not
a major risk factor [2]. There is a range of presentations including pneumonia, liver and splenic
abscesses and septic shock, and the mortality in North-East Thailand is around 40% despite
appropriate antibiotic therapy [3]. Melioidosis is now recognised as endemic in an expanding
number of countries [4]. The prevalence of diabetes in the region is growing, with the reported
Thai prevalence now 6.9% (chiefly Type 2) [5]. Meanwhile changing demographics in the
region leave an increasingly ageing population exposed to the bacterium by farming as younger
family members migrate to urban regions [6]. A vaccine is therefore in demand and cost effec-
tive if targeted towards at-risk groups [7].
The human immune response to melioidosis is far from fully understood. Important roles
for Toll-like receptor (TLR) [8–10], and nucleotide-binding oligomerization domain 2
(NOD2) [11] variants, macrophage function [12] and neutrophil response in diabetic patients
to B. pseudomallei [13,14] have been reported. Up to 80% of people in endemic regions have
serological responses to B. pseudomallei whether they have a history of disease or not [15,16].
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As an intracellular pathogen [17] capable of chronic disease and latency, cellular adaptive
immunity seems likely to be important. There are similarities in the host response to B. pseudo-
mallei and toM. tuberculosis, with both being intracellular, sharing the risk factor of diabetes
[18] and showing similar gene expression profiles dominated by interferon-mediated signalling
pathways [19]. Further support for cellular immunity comes from reports of individuals with
HLA-DRB11602 in Thailand being at increased risk of melioidosis [20]. Murine models have
demonstrated the importance of IFN-γ in survival from experimental challenge [21] and pro-
duction of IFN-γ in response to B. pseudomallei by NK (Natural Killer) cells, CD8+ T-cells and
CD4+ T-cells [22]. In humans, an association between survival from melioidosis and IFN-γ
levels and linked cytokines has been shown [23–25]. Cell mediated immunity has been demon-
strated in Australian patients recovered from melioidosis [26]. Memory T-cell responses to B.
pseudomallei in healthy blood donors in an endemic region and some subjects with previous
melioidosis have been characterised [27]. However the relationship between cellular responses
and survival has not previously been characterised during acute melioidosis.
Vaccine design requires knowledge of naturally acquired immunity, to understand which
bacterial antigens are immunogenic and which components of the immune response are pro-
tective. The development of vaccines against melioidosis is hindered by knowledge gaps [28].
The aim of this study was to see if the cellular responses to B. pseudomallei were related to sur-
vival in patients with melioidosis, and to see the dynamics of the cellular response over one
year in survivors from melioidosis. This work demonstrates an association between lower CD4
+ and CD8+ T-cell responses and mortality from the disease, and shows impaired cellular
immunity in diabetic patients acutely unwell with melioidosis compared to non-diabetic
patients. These findings support an important contribution to control of melioidosis in
humans by cellular immunity.
Materials and Methods
Ethical approval
The study was approved by the ethics committees of Faculty of Tropical Medicine, Mahidol
University (Submission number TMEC 12–014), of Sappasitthiprasong Hospital, Ubon Ratch-
athani (reference 018/2555) and the Oxford Tropical Research Ethics Committee (reference
64–11). The study was conducted according to the principles of the Declaration of Helsinki
(2008) and the International Conference on Harmonization (ICH) Good Clinical Practice
(GCP) guidelines. Written informed consent was obtained for all patients enrolled in the study.
Recruitment of subjects
In-patients at Sappasitthiprasong Hospital, Ubon Ratchathani over 18 years of age with melioi-
dosis were recruited (Melioid Cohort) following positive culture of B. pseudomallei from a clini-
cal specimen, alongside healthy control subjects attending the hospital’s blood donation clinic
(Healthy Control Cohort) and subjects attending the hospital’s diabetes outpatient clinic (Dia-
betes Control Cohort). For patients who did not attend follow-up, their 28 day survival status
was determined by using the hospital mortality records and by telephone.
Blood samples
Subjects enrolled in the study had 25ml of blood drawn for isolation of peripheral blood mono-
nuclear cells (PBMC), serum and glycated haemoglobin (HbA1c) testing for theMelioid and
Diabetes Cohorts. PBMC and plasma were separated by density centrifugation within 3 hours
T-Cell Immunity and Melioidosis
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of blood draw and counted with a Scepter handheld counter (Millipore, UK) before use in fresh
assays.
Antigens for assays
Whole heat-inactivated B. pseudomallei (HIA-Bp) was prepared from two Thai patient isolates
199a and 207a as previously described [29] and used at a dilution of 1:60 (20 μg/ml by Bicinch-
oninic Acid Assay, Sigma) in the ELIspot assay. Phytohemagglutinin (PHA) (final concentra-
tion 5 μg/mL) was added to positive control wells. A T-cell epitope pool (Mabtech, AB, Sweden,
final concentration 1 μg/mL) was used as control antigens.
Ex-vivo interferon-γ (IFN-γ) Enzyme-linked immunosorbent spot-forming
cell assay (ELIspot) and Indirect Haemagglutination Assay (IHA)
The kinetics and magnitude of the cellular response to whole killed B. pseudomallei were
assessed by fresh ex-vivo IFN-γ ELIspot assay. Briefly, 96-well Multiscreen-I plates (Millipore,
UK) were coated overnight with 1D1K anti-human IFN-γ (Mabtech, AB, Sweden) at 4°C. Fresh
PBMCs were added in duplicate wells at 2x105 PBMCs/well and each antigen was added at the
optimal concentration. After 18 hours, secreted IFN-γ was detected according to the manufac-
turer’s instructions (Mabtech, AB, Sweden) and read using a CTL ELIspot reader. Results are
expressed as IFN-γ spot-forming cells (SFC) per million PBMC. Background responses in un-
stimulated control wells were typically less than 20 spots, and were subtracted from those mea-
sured in peptide-stimulated wells. IHA was performed as described previously [29] and a titre
of 1:40 or greater was considered positive [30].
Intracellular staining cytokine assay by flow cytometry
PBMC were stimulated for 18 hours with heat-inactivated B. pseudomallei (50μg/well) or
media. Brefeldin A (Ebioscience, USA) was added at 10 ug/ml and following 4 hours of further
incubation, staining for intracellular APC-IFN-γ and for the immune cell surface markers
PCP-anti-CD3, FITC-anti-CD4, APCH7-anti-CD8, PE-anti-CD56 and V450-CD14 all BD
Biosciences, USA) was performed. Samples were analysed using a MACSQuant Analyzer 10
(Miltenyi Biotec, Germany) with Flowjo software (Treestar Inc, USA). The gating strategy used
to identify the cellular source of IFN-γ after stimulation with heat-killed B. pseudomallei was
firstly selection of singlets to exclude aggregates. The lymphocyte populations were then
selected for immunophenotyping: double positive CD3+CD4+ for CD4 T cells, double positive
CD3+CD8+ for CD8 T cells, double positive CD3+CD56+ for NKT cells and positive CD56
negative CD3 for NK cells. For CD14 positive, cells were gated from singlets. IFN-γ expression
levels were then determined by analysis of each cell phenotype. Responses were quantitated for
the negative control-subtracted percentage of IFN-γ secreted CD4+ or CD8+ cells from the
gated lymphocyte population.
Data management and statistical analysis
Study clinical data were entered into a password-protected web-based database (OpenClinica
version 3.1, LLC and collaborators,Waltham,MA, USA). The presence of diabetes mellitus in
Melioid Cohort subjects was defined for analysis as previous diagnosis by a doctor and / or hav-
ing an HbA1c of 7% [31]. Subjects in theHealthy Control Cohort and Diabetes Control
Cohort were excluded from the analysis if their IHA titre was greater or equal to 1:40, to allow
these cohorts to serve as negative controls. Statistical analysis was performed using Graphpad
Prism version 6 (San Diego, CA, USA) and IBM SPSS Statistics for Windows version 22.0
T-Cell Immunity and Melioidosis
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(Armonk, NY, USA). Non-parametric tests were used (MannWhitney, paired Wilcoxon, Krus-
kal-Wallis and Spearman’s rank correlation tests) and groups were compared with 2-tailed
Fisher’s exact test. To examine the relationship between mortality and the B. pseudomallei-spe-
cific cellular response by ELISpot, a multivariable logistic regression modelling was developed
using a purposeful selection method [32] with logarithmic transformation of non-parametric
data. A P value (2-tailed) of<0.05 was considered significant.
Results
Subjects
200 patients with culture-confirmed acute melioidosis were recruited from September 2012
until September 2014 into theMelioid Cohort and followed up at 12 weeks (n = 113, 57%) and
52 weeks (n = 94, 47%, follow-up ongoing). On average, participants were enrolled on day 5
after admission (median 5, interquartile range IQR 3 to 6 days). The demographics of the sub-
jects in the study are shown in Table 1. The clinical site of culture of B. pseudomallei for the
Melioid Cohort was blood for 105/200 (53%) of cases, with no significant difference between
those with and without diabetes. 172/200 (86%) had at least one identifiable risk factor such as
diabetes, renal or heart disease, alcohol excess or age greater than 65 years. Antibody titres to B.
pseudomallei were greater than or equal to 40 by indirect haemagglutination assay in 75% (95%
CI 68–81) of acute melioidosis patients, consistent with previous reports [1]. 50 subjects were
recruited from diabetes outpatients for the Diabetes Control Cohort, and 5 were excluded from
the analysis for having an IHA40. 50 subjects were recruited from the blood donation clinic
for theHealthy Control Cohort, and 7 were excluded from the analysis for having an IHA40.
Diabetes
117 subjects with acute melioidosis were known to have diabetes on admission, with a mean
HbA1c of 11.1% (median 11.3, IQR 9.1–13.1). The mean HbA1c of the out-patient diabetic con-
trol group was lower at 8.2% (median 7.8, IQR 7.2–9.1) (P< 0.001, Fig 1A). Drug information
was available for 108/117 of subjects admitted with known diabetes and is shown in Fig 1B. 43
subjects (37%) received at least one oral hypoglycaemic drug including the sulphonylurea glipi-
zide (n = 26), metformin (n = 21), glyburide (n = 4), pioglitazone (n = 4) and glimepiride
(n = 1). In addition 17 new diagnoses of diabetes were made on the basis of HbA1c in patients
recruited without a previous history of diabetes.
Table 1. Subject demographics.
Cohort N Gender Age In years Mean (range) Diabetes*
Male n (%) Female n (%) Pre-diagnosed* n (%) Study deﬁnition* n (%)
Melioid Cohort all 200 133 (67%) 67 (33%) 55 (19–89) 117 (59%) 134 (67%)
Melioid Cohort with Diabetes 134 84 (63%) 50 (37%) 53 (19–89) 117 (87%) 134 (100%)
Melioid Cohort no Diabetes 66 49 (74%) 17 (26%) 58 (25–88) 0 (0%) 0 (0%)
Diabetes Controls Cohort 45 30 (67%) 15 (33%) 57 (23–76) 45 (100%) 45 (100%)
Heathy Controls Cohort 43 26 (60%) 17 (40%) 48 (33–73) 0 (0%) 0 (0%)
The gender, age and diabetes status of subjects in the study are shown. Two thirds (67%) of the patients with acute melioidosis were male, with a mean
age of 55 years.
*Diabetes deﬁnitions are as follows: Pre-diagnosed = subjects with a previous diagnosis of diabetes mellitus by a doctor. Study deﬁnition = subjects with
a previous diagnosis of diabetes mellitus by a doctor and / or having an HbA1c of  7%.
doi:10.1371/journal.pntd.0004152.t001
T-Cell Immunity and Melioidosis
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Fig 1. HbA1c for Melioid and Diabetes Cohorts, and treatment received. Fig 1A shows boxplots with Tukey whiskers showing the percentage glycated
haemoglobin (HbA1c) for subjects in theMelioid Cohort (culture-confirmed acute melioidosis) at admission to the study with no diagnosis of Diabetes Mellitus
(Melioid & no DM), with a new diagnosis of Diabetes Mellitus defined for the study as an HbA1c value of7% (Melioid & New Diagnosis DM) and with known
Diabetes Mellitus (Melioid & Known DM) alongside subjects recruited from diabetes out-patient clinic who are (DM outpatient controls).**** P < 0.0001 by
Mann-Whitney test. Fig 1B shows the drug treatment for diabetes on admission for the 117 patients in theMelioid Cohort with previously diagnosed diabetes
mellitus.
doi:10.1371/journal.pntd.0004152.g001
T-Cell Immunity and Melioidosis
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Clinical outcomes
Mortality data was available for 198/200 patients in theMelioid Cohort. 51/198 patients (26%)
died within 28 days of admission to hospital despite correct diagnosis and appropriate choice
of antibiotic. A further 13 patients died after 28 days (from 29 to 90 days). 28 day mortality was
24% (32/133; 95% CI 17–32) for those with diabetes and 29% (19/65; 95% CI 19–42) for those
without diabetes, P = 0.49 by Fisher’s exact test). 15/19 (79%) of the non-diabetic subjects who
died had at least one identifiable risk factor such as liver or renal disease, excessive use of alco-
hol or age greater than 65 years. Increasing age was a risk factor for mortality in univariable
analysis (P = 0.009) but was not an independent risk factor (P = 0.29) in the multivariable logis-
tic regression model. Increasing IHA titres were associated with survival (P = 0.002) in the uni-
variable analysis, but this was not significant by multivariable analysis and did not contribute
to the logistic regression model. Bacteraemia was closely associated with mortality compared
to no bacteraemia (P< 0.0001) with 39/51 (76%) of the deaths occurring in people who were
blood culture positive. The median length of time from admission to hospital until death was
10 days (IQR 5–17), with 35/51 patients taken from hospital to die at home with family. There
was no significant relationship between sulphonylurea use in the diabetic melioidosis patients
and mortality (P = 0.65). Four surviving patients (all with diabetes) had a subsequent diagnosis
of melioidosis 2, 5, 6 and 20 months after study entry, defined by positive culture for B. pseudo-
mallei preceded by negative cultures following standard care including 12 weeks of planned
oral follow-on therapy with co-trimoxazole.
Patients with melioidosis have durable specific T-cell responses to B.
pseudomallei
Cellular immunity to B. pseudomallei was demonstrated in patients with acute melioidosis (Fig
2A). The mean IFN-γ ELIspot response was 133 SFC per million PBMC (median 25, IQR 3 to
99) at Week 0, 262 (median 70, IQR 15 to 265) at Week 12 and 164 (median 30, IQR 10 to 74)
at Week 52. These responses remained elevated at Week 52 compared to the diabetic outpa-
tient controls (mean 37, median 5, IQR 1 to 26, P = 0.004) and healthy seronegative controls
(mean 15, median 5, IQR 1–23, P = 0.0002), whose responses did not differ significantly from
each other (P = 0.99). Responses to control antigens and media are shown in Fig 2B. Pheno-
typic analysis demonstrated IFN-γ production by a range of cell phenotypes including CD4,
CD8, NK and CD14, with the percentage of IFN-γ producing CD8 cells increasingly signifi-
cantly fromWeek 0 to Week 52 (P = 0.01, Fig 2C).
Depressed T-cell responses to B. pseudomallei at admission were
associated with higher mortality rates
The mean cellular response in subjects in theMelioid Cohort who survived the illness was 142
SFC per million PBMC (median 35 IQR 1–145) compared to 98 (median 3 IQR 1–43) for
those who died (Fig 3A). For other antigens tested, there was no significant difference between
survivors and non survivors.
The logistic regression model measured the effect of cellular responses to B. pseudomallei,
neutrophil count, age, diabetes status, and the risk factor of known renal disease on the likeli-
hood that participants died within 28 days of admission with acute melioidosis (Table 2). Log10
transformed data was used for non-parametric distributions. A tenfold increase in B. pseudo-
mallei-specific cellular response was associated with reduction by almost half of the likelihood
of death (OR 0.56, 95% CI 0.36 to 0.88, P = 0.012). Survivors showed an increased frequency of
both CD4+ IFN-γ T-cells (P = 0.04) and CD8+ IFN-γ T-cells (P = 0.009) compared to non-
T-Cell Immunity and Melioidosis
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survivors (Fig 3B). The IFN-γ+ CD8+ fraction was 0.05% or less in 14/14 fatal cases studied
compared to 5/16 of survivor cases.
Subjects who were bacteraemic had lower cellular responses than subjects who were blood
culture negative (P = 0.007). The mean cellular response in subjects in theMelioid Cohort who
were bacteraemic was 99 SFC per million PBMC (median 18 IQR 1–70) compared to 170
(median 46 IQR 5–171) for those who were not bacteraemic.
In the acute stages of melioidosis depressed cellular responses to B.
pseudomallei are observed in patients with diabetes
The cellular response in subjects with acute melioidosis and diabetes was lower than in subjects
with acute melioidosis and no diabetes (mean 101 SFC per million PBMC, median 20, IQR
3–76, compared to mean 198, median 49, IQR 6–196), both at Week 0 (P = 0.03, Fig 4). There
was a non-significant trend for lower responses in subjects with diabetes 12 and 52 weeks later,
when subject numbers were lower. There was a non-significant trend towards higher HbA1c
being associated with lower cellular responses at Week 0 (Spearman’s r = -0.133, P = 0.07) with
no clear trend at subsequent timepoints.
High neutrophil counts during acute melioidosis are associated with
lower B. pseudomallei-specific cellular responses in recovery
A higher neutrophil count on admission was also associated with death (median 12,217 neutro-
phils / μl in fatal cases versus 9,495 neutrophils / μl in survived cases, P = 0.002 on univariable
analysis). In the multivariable model (Table 2) a “J-shaped curve” effect was seen with higher
mortality for both low neutrophil counts (adjusted OR 5.8 [1.1–29.6] for< 4000 neutrophils /
μl compared to> 4000 to 8000) and for higher neutrophil counts (adjusted OR 18.9 [3.1–
114.2] for> 20,000 neutrophils / μl compared to> 4000 to 8000).
The cellular response to B. pseudomallei 12 weeks after the illness showed a tight negative
association with the peripheral neutrophil count on admission to hospital (P< 0.0001, S1 Fig).
This relationship between neutrophil count and cellular response was also present at Week 0
(P = 0.001), and Week 52 (P = 0.008). No such relationship was seen for the control antigens
studied.
Discussion
The results of this study demonstrate a high mortality for patients with melioidosis in Ubon
Ratchathani as previously reported [3]. Work continues in the hospital to audit and improve
the “door-to-needle time” for sepsis patients receiving antibiotics but it should be noted that
not all patients culture positive for B. pseudomallei present to hospital with a classical acute
sepsis syndrome. The mortality predominantly occurred in patients with bacteraemia rather
Fig 2. T-cell Responses to Heat killed B. pseudomallei (Fig 2A) to control antigens (Fig 2B) and by cell
phenotype (Fig 2C). Peripheral blood mononuclear cells (PBMC) from patients with acute melioidosis
(Melioid Cohort Wk0) and 12 (Wk12) and 52 (Wk 52) weeks later were tested alongside PBMC from diabetic
outpatients (Diabetes) and healthy endemic seronegative control subjects (Healthy). Cells were stimulated
with heat-inactivated B. pseudomallei (Fig 2A), a control antigen T-cell epitope pool or media only (Fig 2B) for
18 hours and IFN-γ secreting cells counted and expressed as spot forming cells per million PBMC (SFC/106
PBMC). To characterise the cell phenotype producing IFN-γ, PBMC were incubated with whole B.
pseudomallei for 18 hours and stained for intracellular IFN-γ versus immune cell surface markers (PCP-anti-
CD3, FITC-anti-CD4, APCH7-anti-CD8, PE-anti-CD56 and V450-CD14, Fig 2C). Horizontal lines represent
medians, ***P<0.001, **P<0.01, *P<0.05, ns = not significant, testing by Kruskal-Wallis with Dunn’s
correction for multiple testing.
doi:10.1371/journal.pntd.0004152.g002
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than contained disease, as previously described [33], with no significant difference in mortality
between subjects with diabetes versus no diabetes. Increasing age was a risk factor for death on
univariable analysis as previously reported [34]. Age was not an independent risk factor in the
multivariable model where cellular immunity and neutrophil count were independent predic-
tors of mortality and may represent age-related immune mechanisms of decline.
Lower B. pseudomallei-specific T-cell responses were associated with increased mortality.
Both CD4+ and CD8+ IFN-γ-producing cells were associated with survival. CD4+ cells, but
not CD8+ cells have previously been shown by depletion studies to be important in mediating
immunity against experimental melioidosis in a murine model [35].The additional importance
of CD8 T-cells in control of melioidosis in humans is supported by our finding that the IFN-γ
CD8+ fraction was very low (0.05% or less) in every fatal case whilst the majority of survivors
had higher responses. CD8+ cells have been shown to be a source of IFN-γ during primary
infection of naïve mice [36] or cell lines [37] via bystander activation but the expansion of B.
pseudomallei-specific IFN-γ CD8+ cell fraction at one year compared to during acute illness
supports an adaptive immune role.
The reduced cellular response seen in fatal cases could reflect general immune failure as part
of multi-organ failure in the terminal stages. However no such relationship was seen for
patients in this study with cellular responses to a control T-cell epitope pool. Establishing the
cellular response as having a causal direct role in preventing death, rather than being a marker
of outcome is difficult in patient studies, but the correlation demonstrated here supports the
hypothesis that T-cell responses are important in the control of B. pseudomallei infection in
Fig 3. Ex vivo interferon-gamma ELISPOT responses by survival. Peripheral blood mononuclear cells (PBMC) from patients with acute melioidosis at
study entry (Week 0) were stimulated with heat-inactivated B. pseudomallei (Bp), or a control antigen panel for 18 hours and IFN-γ secreting cells counted
and expressed as spot forming cells per million (SFC/106) PBMC. Responses were compared for survivors and those who died (Fig 3A). To characterise the
cell phenotype producing IFN-γ, PBMC were incubated with whole B. pseudomallei for 18 hours and stained for intracellular IFN-γ versus immune cell
surface markers (PCP-anti-CD3, FITC-anti-CD4 and APCH7-anti-CD8, Fig 3B). Horizontal lines represent medians, ***P<0.001, **P<0.01, *P<0.05,
ns = not significant, by logistic regression adjusted for age, diabetes status, renal disease and neutrophil count for responses in Fig 3A and by Mann-Whitney
test for Fig 3B.
doi:10.1371/journal.pntd.0004152.g003
Table 2. Multivariable analysis for prediction of 28-daymortality in patients with acute melioidosis.
Variable Adjusted Odds Ratio (95% CI) P value
Age 1.0 (0.99–1.1) 0.29
Diabetes 0.56 (0.24–1.3) 0.2
Pre-existing renal disease 3.9 (1.5–10.5) 0.007
Bp cell response 0.56 (0.36–0.88) 0.01
Neutrophil count / μl > 4000–8000 1 1
 4000 5.8 (1.1–29.6) 0.04
> 8000–12,000 8.1 (2.1–31.5) 0.002
> 12,000–20,000 7.5 (1.8–30.6) 0.005
> 20,000 18.9 (3.1–114.2) 0.001
The table displays the odds ratios for variables studied as predictors of mortality in 200 patients with acute
melioidosis in a multivariable logistic regression model. Bp cell response is the log10 transformed ELIspot
response in fresh peripheral blood mononuclear cells to heat-killed B. pseudomallei. Neutrophil count
represents the peripheral blood neutrophil count with > 4000 to 8000 neutrophils / μl as the comparator
group. Odds ratios are adjusted for the other variables included in the model.
doi:10.1371/journal.pntd.0004152.t002
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humans. Further depletion and adoptive transfer studies in animal models are required to
establish causality.
This is the first study to demonstrate the dynamics of the B. pseudomallei-specific cellular
response from acute melioidosis through to follow-up one year later, and the durability of the
IFN-γ response is shown. The IFN-γ responses demonstrated in survivors 12 weeks after
admission with acute melioidosis are compatible with responses reported in a previous study
of T-cell responses to B. pseudomallei using a longer (42 hour) incubation protocol [27]. The
source of the IFN-γ is a combination CD4+ and CD8+ T-cells and Natural Killer cells as previ-
ously shown [27] as well as some monocyte production, and we have shown an increase in the
Fig 4. Ex vivo interferon-gamma ELISPOT Responses to Heat killed Burkholderia pseudomallei by diabetes status. Ex vivo IFN-γ ELIspot responses
to heat-inactivated B. pseudomallei are shown for subjects with melioidosis on admission (Week 0) and 12 (Week12) and 52 (Week 52) weeks later according
to the presence (+) or absence (-) of a diagnosis of Diabetes Mellitus. Peripheral blood mononuclear cells (PBMC) were stimulated with heat-inactivated B.
pseudomallei for 18 hours and IFN-γ secreting cells counted and expressed as spot forming cells per million PBMC (SFC/106 PBMC). Subjects with diabetes
had lower responses to B. pseudomallei during acute illness (Week 0) compared to subjects with no diabetes. Boxplots with Tukey whiskers are shown with
responses greater than 1000 SFC/million PBMC not displayed. ** P < 0.01, ns = not significant by Kruskal-Wallis testing with Dunn’s multiple comparisons
test.
doi:10.1371/journal.pntd.0004152.g004
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B. pseudomallei-specific IFN-γ CD8+ cell fraction at one year compared to during acute illness.
Ongoing studies are evaluating the dynamics of the multifunctional, memory and regulatory
cell subsets over time.
The finding of a “J-shaped curve” association between mortality and peripheral blood neu-
trophil count during acute melioidosis is compatible with the existing literature on the relation-
ship between neutrophils and sepsis [38]. A count in the range of 4000 to 8000 neutrophils/μl
was associated with the lowest mortality, and patients with counts above 20,000 neutrophils/μl
had an adjusted odd ratio for death by 28 days of 18-fold. Neutrophils play a key role in the
host response to B. pseudomallei [13,39,40] bacteria, but excess activation and inappropriate
distribution of neutrophils have been linked to multi-organ failure and poor outcomes in sepsis
[38].
There was an inverse relationship between neutrophil count on admission to hospital and
the cellular response to B. pseudomallei on admission, 12 weeks later and 52 weeks later for sur-
vivors. Excess neutrophil activation may represent a shift in the development of hematopoietic
stem cell progenitors in the bone marrow from lymphoid lineage to myeloid lineage. Although
neutrophils are generally believed to support antigen presentation and the development of spe-
cific adaptive responses through multiple pro-inflammatory processes, the relationship is com-
plex. Studies have shown inhibition of T-cell responses by neutrophils in bacterial sepsis [41]
and by related immature myeloid cells named myeloid derived suppressor cells (MDSCs) [42].
A recent elegant study demonstrated that CD4+ T-cell proliferation and IFN-γ production in
response to polyclonal activators is inhibited by B. pseudomallei-infected neutrophils via Pro-
grammed death ligand 1 (PD-L1) [14]. Overall, for generation of adaptive immune responses
to B. pseudomallei excessive neutrophil activation and B. pseudomallei invasion of neutrophils
may be detrimental to the optimal priming environment.
This study shows people with diabetes and acute melioidosis have a depressed cellular
response to the bacteria than people without diabetes. This stunted cellular response is of inter-
est because of the increased risk of melioidosis in people with diabetes. The mechanisms of
immune dysregulation to intracellular pathogens seen in diabetes are an ongoing focus of
research [43]. There are parallels to the relationship between adaptive immunity to tuberculosis
and diabetes [44]. In the diabetic mouse model of aerosol challenge with tuberculosis [45],
lower IFN-γ levels in the lung were found early in the infection (2 weeks post challenge) com-
pared to non-diabetic mice, but the difference in IFN-γ levels had disappeared by 4 weeks. A
temporal delay in the adaptive cellular response to TB was associated with poor early control of
intracellular bacteria and ultimately a higher bacterial burden and more inflammation [46].
Our data support a similar relationship in humans and B. pseudomallei.
Although patients with diabetes had lower cellular responses to B. pseudomallei while
acutely unwell, and lower cellular responses were associated with increased mortality, patients
with diabetes did not have an increased mortality in this study, and diabetes was not an inde-
pendent predictor of death in the multivariable logistic regression model. Previous studies have
reported a survival benefit from the diabetes drug glyburide [47] but only one patient in this
study took glyburide and use of any sulphonylurea drug was not associated with mortality. Elu-
cidation of the susceptibility of diabetics to this bacterium will have wider implications for pre-
vention of infections in diabetics and those with immune failure.
Patients with melioidosis and underlying known diabetes have poor glycaemic control com-
pared to diabetic out-patients in the region. Healthy patients attending a diabetes outpatient
clinic are unlikely to represent the same population because these are people actively engaging
with management of their diabetes by attending clinic, whilst the patients in theMelioid Cohort
have come to medical services because of acute illness. Nevertheless the fact that all but seven
patients in theMelioid Cohort population with pre-diagnosed diabetes were receiving drug
T-Cell Immunity and Melioidosis
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therapy, including insulin in the majority of cases, is evidence of receiving diabetes care. The
interaction between diabetes and tuberculosis, another intracellular pathogen, is well known
[48], and tuberculosis is reported to worsen glycaemic control [49]. We hypothesise that
chronic exposure to B. pseudomalleimay worsen glycaemic control. Because of the impact of
rising prevalence of diabetes in Thailand [5] on morbidly and mortality, exacerbation by wide-
spread B. pseudomallei exposure would have major public health implications. Longitudinal
study of the relationship between B. pseudomallei presence in fields, human infection and gly-
caemic control are warranted.
Conclusions
This is the first study to measure the kinetics of a cellular immune response in from acute dis-
ease to long-term follow-up, and link results to outcome. Lower cellular responses are associ-
ated with increased mortality, supporting a pivotal role for cellular immunity in controlling
this bacterium. The development of vaccine strategies that seek to enhance both cell mediated
and humoral immunity may be beneficial for successful control of this disease.
Supporting Information
S1 Fig. Relationship between neutrophil count on admission (Week 0) and cellular
response to B. pseudomallei on admission, 12 and 52 weeks later. The neutrophil count in
cells per microliter for patients acutely unwell with melioidosis (Melioid Cohort Week 0)
showed a negative correlation with the IFN-γ ELIspot response to B. pseudomallei (in spot
forming cells per million peripheral blood mononuclear cells = SFC/106 PBMC) for the same
patients on admission (Week 0) and following recovery 12 and 52 weeks later, calculated by
Spearman’s rank correlation coefficient.
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